• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pneumonia. >Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis
【24h】

Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis

机译：耐药结核病和儿童结核病的治疗进展

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Over the last 10?years, interest in pediatric tuberculosis (TB) has increased dramatically, together with increased funding and research. We have a better understanding of the burden of childhood TB as well as a better idea of how to diagnose it. Our appreciation of pathophysiology is improved and with it investigators are beginning to consider pediatric TB as a heterogeneous entity, with different types and severity of disease being treated in different ways. There have been advances in how to treat both TB infection and TB disease caused by both drug-susceptible as well as drug-resistant organisms. Two completely novel drugs, bedaquiline and delamanid, have been developed, in addition to the use of older drugs that have been re-purposed. New regimens are being evaluated that have the potential to shorten treatment. Many of these drugs and regimens have first been investigated in adults with children an afterthought, but increasingly children are being considered at the outset and, in some instances studies are only conducted in children where pediatric-specific issues exist.
机译：在过去的10年中，随着资金和研究的增加，对小儿结核病（TB）的兴趣急剧增加。我们对儿童结核病的负担有了更好的了解，并且对如何诊断它有了更好的了解。我们对病理生理学的认识得到了提高，研究者开始将其视为一种异质性实体，对不同类型和严重程度的疾病采用不同的治疗方法。在如何治疗由药物敏感性和耐药性引起的结核感染和结核病方面已有进展。除了使用已重新用途的较旧药物外，还开发了两种新药贝达喹啉和德拉曼尼德。正在评估可能缩短治疗时间的新方案。首先对有孩子的成年人进行了研究，其中许多药物和治疗方案是事后才考虑的，但一开始就考虑使用儿童，在某些情况下，研究仅在存在儿科特定问题的儿童中进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号